Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that the European Commission has granted Orphan Medicinal Product Designation to sapablursen (ONO-0530) in polycythemia vera (PV). Sapablursen has previously received Fast Track Designation in January 2024, Orphan Drug Designation in August 2024, and Breakthrough Therapy Designation in May 2025 from the U.S. Food and Drug Administration (FDA). In Japan, sapablursen received Orphan Drug Designation in September 2026.

In addition, a trial-in-progress poster about the global Phase 3, double-blind, randomized controlled INTREPID study of sapablursen in patients with PV, which is being developed by Deciphera, Ono’s U.S. subsidiary, will be presented at the 68th American Society of Hematology Annual Meeting, being held December 12-15, 2026, in New Orleans, Louisiana.

The poster presentation details are as follows:

Title: Trial in Progress: INTREPID: A global, randomized, double-blind, placebo-controlled Phase 3 study of sapablursen in patients with phlebotomy-dependent polycythemia vera

Presenter: Pankit Vachhani, M.D., Associate Professor of Medicine at O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham

Session #: Title: 634, Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II

Date and Time: Sunday, December 13, 2026, 6:00 – 8:00 PM CDT

Location: MCCNO – Hall F

Poster #: 3771

About Sapablursen (ONO-0530)

Sapablursen, an antisense oligonucleotide, is designed to reduce the production of TMPRSS6, a negative regulator of hepcidin. Reducing TMPRSS6 is intended to increase hepcidin, the key regulator of iron homeostasis. By increasing the production of hepcidin, sapablursen has the potential to positively impact polycythemia vera by decreasing hematocrit, reducing the need for phlebotomy, and improving quality of life.

About Polycythemia Vera

Polycythemia vera (PV) is a rare and potentially life-threatening hematologic disease characterized by the overproduction of red blood cells, which significantly increases the risk of serious blood clots, heart attack, stroke, and death. The primary treatment goal in PV is to maintain blood hematocrit levels <45% to prevent thrombotic events and alleviate burdensome symptoms, such as severe fatigue, difficulty concentrating, night sweats, and pruritus. Despite available treatment options, some patients continue to experience burdensome symptoms or inadequate hematocrit control.

About Deciphera Pharmaceuticals Inc.

Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to help people live longer, healthier lives. We harness cutting-edge technologies including advanced kinase-inhibitor science, data analytics, and AI-enabled drug discovery to accelerate breakthroughs in our key focus areas; oncology, immunology & inflammation and neurology. Headquartered in Waltham, MA with research facilities in Lawrence, KS, Deciphera is leading Ono’s expansion in the U.S. and Europe with both commercial products and a robust pipeline of clinical programs with first- or best-in-class potential. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. delivers innovative medicines for patients worldwide. Upholding its philosophy of “Dedicated to the Fight against Disease and Pain,” Ono targets areas with unmet medical needs including oncology, immunology & inflammation, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company’s website at https://www.ono-pharma.com/en.

Cautionary Note Regarding Forward-Looking Statements

In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice.

Media gallery

About The Author
Business Wire